Stay updated with breaking news from Epigenetic Regulator Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DURECT (NASDAQ:DRRX – Get Rating) released its earnings results on Monday. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02, MarketWatch Earnings reports. DURECT had a negative return on equity of 58.72% and a negative net margin of 280.15%. During the same period in […]
DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs Webcast of Earnings Call Today, May 4th at 4:30 p.m. ET News provided by Share this article Share this article CUPERTINO, Calif., May 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2021 and provided a corporate update. Q1 2021 Accomplishments: Initiated patient dosing in the Phase 2b AHFIRM clinical study of DUR-928 in severe Alcohol-associated Hepatitis (AH) FDA approval of POSIMIR in adults to produce post-surgical analg...